title: Transplantation in Parkinson's disease: PET changes correlate with the amount of grafted tissue.
abstract: We compared the striatal uptake of [(18)F]fluorodopa with [(76)Br]-FE-CBT, a positron emission tomography (PET) ligand of the dopamine transporter (DAT), which estimates the density of dopamine nerve terminals, in 6 patients with Parkinson's disease grafted with fetal mesencephalic cells. There was no change in DAT ligand binding in the grafted putamen, despite a significant increase of [(18)F]fluorodopa uptake. This finding suggests that the clinical benefit induced by the graft is more related to increased dopaminergic activity than improved dopaminergic innervation in the host striatum and, therefore, that [(18)F]fluorodopa remains the optimal tracer to evaluate grafted PD patients. Further analysis showed that the clinical and [(18)F]fluorodopa uptake changes after the grafts were correlated with the number of ventral mesencephalae used for implantation.
authors.affiliation: Unité de Recherche Associée Commissariat à l'Energie Atomique (CEA)-Centre National de la Recherche Scientifique (CNRS) 2210, Orsay, France.
authors.forename: Valérie
authors.initials: V
authors.lastname: Cochen
authors.forename: Maria-Joao
authors.initials: MJ
authors.lastname: Ribeiro
authors.forename: Jean-Paul
authors.initials: JP
authors.lastname: Nguyen
authors.forename: Jean-Marc
authors.initials: JM
authors.lastname: Gurruchaga
authors.forename: Gabriel
authors.initials: G
authors.lastname: Villafane
authors.forename: Christian
authors.initials: C
authors.lastname: Loc'h
authors.forename: Gilles
authors.initials: G
authors.lastname: Defer
authors.forename: Yves
authors.initials: Y
authors.lastname: Samson
authors.forename: Marc
authors.initials: M
authors.lastname: Peschanski
authors.forename: Philippe
authors.initials: P
authors.lastname: Hantraye
authors.forename: Pierre
authors.initials: P
authors.lastname: Cesaro
authors.forename: Philippe
authors.initials: P
authors.lastname: Remy
mesh_terms: D000368:Aged; D003342:Corpus Striatum / Q000378:metabolism*; D050483:Dopamine Plasma Membrane Transport Proteins; D005260:Female; D016332:Fetal Tissue Transplantation / Q000379:methods; D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics*; D006084:Graft Rejection / Q000517:prevention & control; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D008562:Membrane Glycoproteins; D026901:Membrane Transport Proteins / Q000378:metabolism; D008636:Mesencephalon / Q000196:embryology / Q000378:metabolism* / Q000637:transplantation*; D008875:Middle Aged; D009419:Nerve Tissue Proteins; D010300:Parkinson Disease / Q000175:diagnosis* / Q000601:surgery*; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics*; D014055:Tomography, Emission-Computed
chemical_list: D050483:Dopamine Plasma Membrane Transport Proteins; D007166:Immunosuppressive Agents; D008562:Membrane Glycoproteins; D026901:Membrane Transport Proteins; D009419:Nerve Tissue Proteins; D019275:Radiopharmaceuticals; C493214:SLC6A3 protein, human; D019788:Fluorodeoxyglucose F18